Granulomatous vasculitis, microscopic polyangiitis and primary angiitis of the central nervous system

Textbook of Pediatric Rheumatology

Volumn , Issue , 2011, Pages 521-543

  Cabral, David ^a   Benseler, Susanne ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882554769     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-6581-4.10034-2     Document Type: Chapter

References (415)

1. Cotch M.F., Hoffman G.S., Yerg D.E., et al. The epidemiology of Wegener's granulomatosis. Estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources,. Arthritis Rheum 1996, 39:87-92.
2. Gardner-Medwin J.M., Dolezalova P., Cummins C., et al. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002, 360:1197-1202.
3. Wilkinson N.M., Page J., Uribe A.G., et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J. Rheumatol 2007, 34:224-226.
4. Belostotsky V.M., Shah V., Dillon M.J. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr. Nephrol 2002, 17:754-761.
5. Fries J.F., Hunder G.G., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990, 33:1135-1136.
6. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
7. Ozen S., Ruperto N., Dillon M.J., et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann. Rheum. Dis 2006, 65:936-941.
8. Cabral D.A., Uribe A.G., Benseler S.M., et al. Classification, presentation and initial treatment of Wegener's Granulomatosis in childhood. Arthritis Rheum 2009, 60:3413-3424.
9. Rottem M., Fauci A.S., Hallahan C.W., et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J. Pediatr 1993, 122:26-31.
10. Akikusa J.D., Schneider R., Harvey E.A., et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007, 57:837-844.
11. Kallenberg C.G. Pathogenesis of PR3-ANCA associated vasculitis. J. Autoimmun 2008, 30:29-36.
12. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med 1992, 116:488-498.
13. Savige J.A., Davies D.J., Gatenby P.A. Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report from workshops. Pathology 1994, 26:186-193.
14. Jennette J.C., Falk R.J. Small-vessel vasculitis. N. Engl. J. Med 1997, 337:1512-1523.
15. Little M.A., Smyth C.L., Yadav R., et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005, 106:2050-2058.
16. Fauci A.S., Haynes B.F., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med 1983, 98:76-85.
17. Leavitt R.Y., Fauci A.S., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis,. Arthritis Rheum 1990, 33:1101-1107.
18. Lie J.T. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990, 33:1074-1087.
19. McGregor M.B., Sandler G. Wegener's Granulomatosis. A clinical and radiological survey. Br. J. Radiol 1964, 37:430-439.
20. Cordier J.F., Valeyre D., Guillevin L., et al. Pulmonary Wegener's granulomatosis. A clinical and imaging study of 77 cases. Chest 1990, 97:906-912.
21. Moorthy A.V., Chesney R.W., Segar W.E., et al. Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy. J. Pediatr 1977, 91:616-618.
22. Gottlieb B.S., Miller L.C., Ilowite N.T. Methotrexate treatment of Wegener granulomatosis in children. J. Pediatr 1996, 129:604-607.
23. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198.
24. de Groot G.K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med 2009, 150:670-680.
25. Reinhold-Keller E., Fink C.O., Herlyn K., et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002, 47:326-332.
26. WGET Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med 2005, 352:351-361.
27. de Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469.
28. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med 2003, 349:36-44.
29. Langford C.A., Talar-Williams C., Barron K.S., et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am. J. Med 2003, 114:463-469.
30. Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med 2008, 359:2790-2803.
31. Lanham J.G., Elkon K.B., Pusey C.D., et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63:65-81.
32. Zwerina J., Eger G., Englbrecht M., et al. Churg-Strauss Syndrome in Childhood: A Systematic Literature Review and Clinical Comparison with Adult Patients,. Semin. Arthritis Rheum 2008, 39:108-115.
33. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome. Clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78:26-37. 1999.
34. Guillevin L., Guittard T., Bletry O., et al. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987, 165:165-172.
35. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
36. Savage C.O., Winearls C.G., Evans D.J., et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q. J. Med 1985, 56:467-483.
37. Watts R.A., Jolliffe V.A., Carruthers D.M., et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996, 39:1208-1212.
38. Hattori M., Kurayama H., Koitabashi Y. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J. Am. Soc. Nephrol 2001, 12:1493-1500.
39. Besbas N., Ozen S., Saatci U., et al. Renal involvement in polyarteritis nodosa: evaluation of 26 Turkish children. Pediatr. Nephrol 2000, 14:325-327.
40. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421-430.
41. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest 2002, 110:955-963.
42. Bakkaloglu A., Ozen S., Baskin E., et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa,. Arch. Dis. Child 2001, 85:427-430.
43. Gayraud M., Guillevin L., le Toulemin P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
44. Cravioto H., Feigin I. Noninfectious granulomatous angiitis with predilection for the nervous system. Neurology 1959, 9:599-609.
45. Calabrese L.H., Mallek J.A. Primary angiitis of the central nervous system: report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 1988, 67:20-39.
46. Lanthier S., Lortie A., Michaud J., et al. Isolated angiitis of the CNS in children. Neurology 2001, 56:837-842.
47. Gallagher K.T., Shaham B., Reiff A., et al. Primary angiitis of the central nervous system in children: 5 cases. J. Rheumatol 2001, 28:616-623.
48. Benseler S.M., Silverman E., Aviv R.I., et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006, 54:1291-1297.
49. Benseler S.M., deVeber G., Hawkins C., et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005, 52:2159-2167.
50. Banwell B., Tenembaum S., Lennon V.A., et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008, 70:344-352.
51. Florance N.R., Davis R.L., Lam C., et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann. Neurol 2009, 66:11-18.
52. Moshous D., Feyen O., Lankisch P., et al. Primary necrotizing lymphocytic central nervous system vasculitis due to perforin deficiency in a four-year-old girl. Arthritis Rheum 2007, 56:995-999.
53. K.G. Werner, C.F. Morel, A. Kirton, et al: RoME: Rolandic Mitochondrial Encephalomyelopathy with Epilepsia Partialis Continua and ND3 mutations, Ped Neurol accepted for publication, 2009.
54. Elbers J., Benseler S.M. Central nervous system vasculitis in children. Curr. Opin. Rheumatol 2008, 20:47-54.
55. Ganesan V., Chong W.K., Cox T.C., et al. Posterior circulation stroke in childhood: risk factors and recurrence. Neurology 2002, 59:1552-1556.
56. Askalan R., Laughlin S., Mayank S., et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001, 32:1257-1262.
57. Golomb M.R., Fullerton H.J., Nowak-Gottl U., et al. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. Stroke 2009, 40:52-57.
58. Venkateswaran S., Hawkins C., Wassmer E. Diagnostic yield of brain biopsies in children presenting to neurology. J. Child Neurol 2008, 23:253-258.
59. Kuker W., Gaertner S., Nagele T., et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis. Cerebrovasc. Dis 2008, 26:23-29.
60. McKeon A., Lennon V.A., Lotze T., et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008, 71:93-100.
61. Aviv R.I., Benseler S.M., Silverman E.D., et al. MR imaging and angiography of primary CNS vasculitis of childhood. AJNR 2006, 27:192-199.
62. Aviv R.I., Benseler S.M., DeVeber G., et al. Angiography of primary central nervous system angiitis of childhood: conventional angiography versus magnetic resonance angiography at presentation. AJNR 2007, 28:9-15.
63. Dale R.C., Brilot F., Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr. Opin. Neurol 2009, 22:233-240.
64. Jacob A., Weinshenker B.G., Violich I., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neuro 2008, 65:1443-1448.
65. Kirsten A., Beck S., Fuhlhuber V., et al. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann. N. Y. Acad. Sci 2007, 1110:256-260.
66. Friedmann I. McBride and the midfacial granuloma syndrome. (The second 'McBride Lecture', Edinburgh, 1980). J. Laryngol. Otol 1982, 96:1-23.
67. Klinger H. Grenzformen der polyarteritis nodosa. Z. Pathol 1931, 42:455.
68. Wegener F. On generalised septic vessel diseases. Thorax 1987, 42:918-919.
69. Koldingsnes W., Nossent H. Epidemiology of Wegener's granulomatosis in northern Norway. Arthritis Rheum 2000, 43:2481-2487.
70. Cotch M.F., Hoffman G.S., Yerg D.E., et al. The epidemiology of Wegener's granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum 1996, 39:87-92.
71. Watts R.A., Lane S.E., Bentham G., et al. Epidemiology of systemic vasculitis: a ten-year study in the United Kingdom. Arthritis Rheum 2000, 43:414-419.
72. Gardner-Medwin J.M., Dolezalova P., Cummins C., et al. Incidence of Henoch-Schönlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins. Lancet 2002, 360:1197-1202.
73. Dolezalova P., Telekesova P., Nemcova D., et al. Incidence of vasculitis in children in the Czech Republic: 2-year prospective epidemiology survey. J. Rheumatol 2004, 31:2295-2299.
74. Wilkinson N.M., Page J., Uribe A.G., et al. Establishment of a pilot pediatric registry for chronic vasculitis is both essential and feasible: a Childhood Arthritis and Rheumatology Alliance (CARRA) survey. J. Rheumatol 2007, 34:224-226.
75. Belostotsky V.M., Shah V., Dillon M.J. Clinical features in 17 paediatric patients with Wegener granulomatosis. Pediatr. Nephrol 2002, 17:754-761.
76. Fries J.F., Hunder G.G., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis. Summary. Arthritis Rheum 1990, 33:1135-1136.
77. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994, 37:187-192.
78. Ozen S., Ruperto N., Dillon M.J., et al. EULAR/PReS endorsed consensus criteria for the classification of childhood vasculitides. Ann. Rheum. Dis 2006, 65:936-941.
79. Cabral D.A., Uribe A.G., Benseler S.M., et al. Classification, presentation and initial treatment of Wegener's granulomatosis in childhood. Arthritis Rheum 2009, 60:3413-3424.
80. Knight A., Ekbom A., Brandt L., et al. Increasing incidence of Wegener's granulomatosis in Sweden, 1975-2001. J. Rheumatol 2006, 33:2060-2063.
81. Takala J.H., Kautiainen H., Malmberg H., et al. Incidence of Wegener's granulomatosis in Finland 1981-2000. Clin. Exp. Rheumatol 2008, 26:S81-S85.
82. Watts R.A., Lane S.E., Scott D.G., et al. Epidemiology of vasculitis in Europe. Ann. Rheum. Dis 2001, 60:1156-1157.
83. Watts R.A., Gonzalez-Gay M.A., Lane S.E., et al. Geoepidemiology of systemic vasculitis: comparison of the incidence in two regions of Europe. Ann. Rheum. Dis 2001, 60:170-172.
84. O'Donnell J.L., Stevanovic V.R., Frampton C., et al. Wegener's granulomatosis in New Zealand: evidence for a latitude-dependent incidence gradient. Intern. Med. J 2007, 37:242-246.
85. Rottem M., Fauci A.S., Hallahan C.W., et al. Wegener granulomatosis in children and adolescents: clinical presentation and outcome. J. Pediatr 1993, 122:26-31.
86. Akikusa J.D., Schneider R., Harvey E.A., et al. Clinical features and outcome of pediatric Wegener's granulomatosis. Arthritis Rheum 2007, 57:837-844.
87. Kallenberg C.G. Pathogenesis of PR3-ANCA associated vasculitis. J. Autoimmun 2008, 30:29-36.
88. Hagen E.C., Stegeman C.A., D'Amaro J., et al. Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int 1995, 48:801-805.
89. Stassen P.M., Cohen-Tervaert J.W., Lems S.P., et al. HLA-DR4, DR13(6) and the ancestral haplotype A1B8DR3 are associated with ANCA-associated vasculitis and Wegener's granulomatosis. Rheumatology (Oxford) 2009, 48:622-625.
90. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann. Intern. Med 1992, 116:488-498.
91. Knudsen B.B., Joergensen T., Munch-Jensen B. Wegener's granulomatosis in a family: a short report. Scand. J. Rheumatol 1988, 17:225-227.
92. Stoney P.J., Davies W., Ho S.F., et al. Wegener's granulomatosis in two siblings: a family study. J. Laryngol. Otol 1991, 105:123-124.
93. Hay E.M., Beaman M., Ralston A.J., et al. Wegener's granulomatosis occurring in siblings. Br. J. Rheumatol 1991, 30:144-145.
94. Nowack R., Lehmann H., Flores-Suarez L.F., et al. Familial occurrence of systemic vasculitis and rapidly progressive glomerulonephritis. Am. J. Kidney Dis 1999, 34:364-373.
95. Lane S.E., Watts R.A., Bentham G., et al. Are environmental factors important in primary systemic vasculitis? A case-control study. Arthritis Rheum 2003, 48:814-823.
96. Tervaert J.W., Stegeman C.A., Kallenberg C.G. Silicon exposure and vasculitis. Curr. Opin. Rheumatol 1998, 10:12-17.
97. Knight A., Sandin S., Askling J. Occupational risk factors for Wegener's granulomatosis: a case control study. Ann. Rheum. Dis 2009, 69:737-740.
98. Stegeman C.A., Tervaert J.W., Sluiter W.J., et al. Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis. Ann. Intern. Med 1994, 120:12-17.
99. van der Woude F.J., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener's granulomatosis. Lancet 1985, 1:425-429.
100. Savige J.A., Davies D.J., Gatenby P.A. Anti-neutrophil cytoplasmic antibodies (ANCA): their detection and significance: report from workshops. Pathology 1994, 26:186-193.
101. Savige J. Testing for antineutrophil cytoplasmic antibodies. Expert. Rev. Mol. Diagn 2001, 1:281-289.
102. Jennette J.C., Falk R.J. Small-vessel vasculitis. N. Engl. J. Med 1997, 337:1512-1523.
103. Little M.A., Smyth C.L., Yadav R., et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005, 106:2050-2058.
104. Schreiber A., Busjahn A., Luft F.C., et al. Membrane expression of proteinase 3 is genetically determined. J. Am. Soc. Nephrol 2003, 14:68-75.
105. Witko-Sarsat V., Lesavre P., Lopez S., et al. A large subset of neutrophils expressing membrane proteinase 3 is a risk factor for vasculitis and rheumatoid arthritis. J. Am. Soc. Nephrol 1999, 10:1224-1233.
106. Schreiber A., Otto B., Ju X., et al. Membrane proteinase 3 expression in patients with Wegener's granulomatosis and in human hematopoietic stem cell-derived neutrophils. J. Am. Soc. Nephrol 2005, 16:2216-2224.
107. Rarok A.A., Stegeman C.A., Limburg P.C., et al. Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis. J. Am. Soc. Nephrol 2002, 13:2232-2238.
108. Nowack R., Grab I., Flores-Suarez L.F., et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCA-associated vasculitis. Nephrol. Dial. Transplant 2001, 16:1631-1637.
109. Boomsma M.M., Stegeman C.A., van der Leij M.J., et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000, 43:2025-2033.
110. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care Med 2006, 173:180-187.
111. Aries P.M., Hellmich B., Voswinkel J., et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann. Rheum. Dis 2006, 65:853-858.
112. Franssen C.F., Stegeman C.A., Kallenberg C.G., et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000, 57:2195-2206.
113. Csernok E., Trabandt A., Muller A., et al. Cytokine profiles in Wegener's granulomatosis: predominance of type 1 (Th1) in the granulomatous inflammation. Arthritis Rheum 1999, 42:742-750.
114. Popa E.R., Stegeman C.A., Kallenberg C.G., et al. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 2002, 4:77-79.
115. Popa E.R., Stegeman C.A., Bos N.A., et al. Staphylococcal superantigens and T cell expansions in Wegener's granulomatosis. Clin. Exp. Immunol 2003, 132:496-504.
116. Csernok E., Ernst M., Schmitt W., et al. Activated neutrophils express proteinase 3 on their plasma membrane in vitro and in vivo. Clin. Exp. Immunol 1994, 95:244-250.
117. Waldherr R., Noronha I.L., Niemir Z., et al. Expression of cytokines and growth factors in human glomerulonephritides. Pediatr. Nephrol 1993, 7:471-478.
118. Ludviksson B.R., Sneller M.C., Chua K.S., et al. Active Wegener's granulomatosis is associated with HLA-DR+ CD4+ T cells exhibiting an unbalanced Th1-type T cell cytokine pattern: reversal with IL-10. J. Immunol 1998, 160:3602-3609.
119. Muller A., Trabandt A., Gloeckner-Hofmann K., et al. Localized Wegener's granulomatosis: predominance of CD26 and IFN-gamma expression. J. Pathol 2000, 192:113-120.
120. Rastaldi M.P., Ferrario F., Crippa A., et al. Glomerular monocyte-macrophage features in ANCA-positive renal vasculitis and cryoglobulinemic nephritis. J. Am. Soc. Nephrol 2000, 11:2036-2043.
121. Tse W.Y., Abadeh S., Jefferis R., et al. Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin. Exp. Immunol 2000, 119:574-577.
122. Tse W.Y., Abadeh S., McTiernan A., et al. No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis. Clin. Exp. Immunol 1999, 117:198-205.
123. Edberg J.C., Wainstein E., Wu J., et al. Analysis of FcgammaRII gene polymorphisms in Wegener's granulomatosis. Exp. Clin. Immunogenet 1997, 14:183-195.
124. Dijstelbloem H.M., Scheepers R.H., Oost W.W., et al. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum 1999, 42:1823-1827.
125. Muller A., Lamprecht P. Interleukin-17 in chronic inflammatory and autoimmune diseases: rheumatoid arthritis, Crohn's disease and Wegener's granulomatosis. Z. Rheumatol 2008, 67:72-74.
126. Wilson N.J., Boniface K., Chan J.R., et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol 2007, 8:950-957.
127. Stone J.H. Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial. Arthritis Rheum 2003, 48:2299-2309.
128. Stegmayr B.G., Gothefors L., Malmer B., et al. Wegener granulomatosis in children and young adults: a case study of ten patients. Pediatr. Nephrol 2000, 14:208-213.
129. Hall S.L., Miller L.C., Duggan E., et al. Wegener granulomatosis in pediatric patients. J. Pediatr 1985, 106:739-744.
130. Fauci A.S., Haynes B.F., Katz P., et al. Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. Ann. Intern. Med 1983, 98:76-85.
131. Miyahara N., Eda R., Umemori Y., et al. Pulmonary lymphoma of large B-cell type mimicking Wegener's granulomatosis. Intern. Med 2001, 40:786-790.
132. Hasni S.A., Gruber B.L. Sarcoidosis presenting as necrotizing sinus destruction mimicking Wegener's granulomatosis. J. Rheumatol 2000, 27:512-514.
133. Stebbing J., Askin F., Fishman E., et al. Pulmonary manifestations of ulcerative colitis mimicking Wegener's granulomatosis. J. Rheumatol 1999, 26:1617-1621.
134. Devaney K.O., Travis W.D., Hoffman G., et al. Interpretation of head and neck biopsies in Wegener's granulomatosis: a pathologic study of 126 biopsies in 70 patients. Am. J. Surg. Pathol 1990, 14:555-564.
135. Leavitt R.Y., Fauci A.S., Bloch D.A., et al. The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990, 33:1101-1107.
136. von S.E., Lu T.T., Emery H.M., et al. Thrombosis and pediatric Wegener's granulomatosis: acquired and genetic risk factors for hypercoagulability. Arthritis Rheum 2003, 49:862-865.
137. Csernok E., Holle J., Hellmich B., et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2004, 43:174-180.
138. Jennette J.C., Wilkman A.S., Falk R.J. Anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and vasculitis. Am. J. Pathol 1989, 135:921-930.
139. Chen M., Yu F., Zhang Y., et al. Characteristics of Chinese patients with Wegener's granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int 2005, 68:2225-2229.
140. Jennette J.C., Falk R.J. Diagnostic classification of antineutrophil cytoplasmic autoantibody-associated vasculitides. Am. J. Kidney Dis 1991, 18:184-187.
141. Nolle B., Specks U., Ludemann J., et al. Anticytoplasmic autoantibodies: their immunodiagnostic value in Wegener granulomatosis. Ann. Intern. Med 1989, 111:28-40.
142. Jennette J.C., Falk R.J. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am. J. Clin. Pathol 1993, 99:221-223.
143. Lie J.T. Illustrated histopathologic classification criteria for selected vasculitis syndromes. American College of Rheumatology Subcommittee on Classification of Vasculitis. Arthritis Rheum 1990, 33:1074-1087.
144. Fahey J.L., Leonard E., Churg J., et al. Wegener's granulomatosis. Am. J. Med 1954, 17:168-179.
145. Weiss M.A., Crissman J.D. Renal biopsy findings in Wegener's granulomatosis: segmental necrotizing glomerulonephritis with glomerular thrombosis. Hum. Pathol 1984, 15:943-956.
146. Roback S.A., Herdman R.C., Hoyer J., et al. Wegener's granulomatosis in a child: observations on pathogenesis and treatment. Am. J. Dis. Child 1969, 118:608-614.
147. Rubin D., Peterson P., Meltzer J.I. Letter: Renal lesions in Wegener's granulomatosis. Ann. Intern. Med 1975, 82:849-850.
148. Moore T.L., Osborn T.G., Weiss T.D., et al. Autoantibodies in juvenile arthritis. Sem. Arthriis Rheum 1984, 13:329-336.
149. Wolff S.M., Fauci A.S., Horn R.G., et al. Wegener's granulomatosis. Ann. Intern. Med 1974, 81:513-525.
150. McGregor M.B., Sandler G. Wegener's granulomatosis: A clinical and radiological survey. Br. J. Radiol 1964, 37:430-439.
151. Cordier J.F., Valeyre D., Guillevin L., et al. Pulmonary Wegener's granulomatosis: a clinical and imaging study of 77 cases. Chest 1990, 97:906-912.
152. Reuter M., Schnabel A., Wesner F., et al. Pulmonary Wegener's granulomatosis: correlation between high-resolution CT findings and clinical scoring of disease activity. Chest 1998, 114:500-506.
153. Connolly B., Manson D., Eberhard A., et al. CT appearance of pulmonary vasculitis in children. Am. J. Roentgenol 1996, 167:901-904.
154. Asmus R., Koltze H., Muhle C., et al. MRI of the head in Wegener's granulomatosis. Adv. Exp. Med. Biol 1993, 336:319-321.
155. Muhle C., Reinhold-Keller E., Richter C., et al. MRI of the nasal cavity, the paranasal sinuses and orbits in Wegener's granulomatosis. Eur. Radiol 1997, 7:566-570.
156. Allen S.D., Harvey C.J. Imaging of Wegener's granulomatosis. Br. J. Radiol 2007, 80:757-765.
157. Moorthy A.V., Chesney R.W., Segar W.E., et al. Wegener granulomatosis in childhood: prolonged survival following cytotoxic therapy. J. Pediatr 1977, 91:616-618.
158. Gottlieb B.S., Miller L.C., Ilowite N.T. Methotrexate treatment of Wegener granulomatosis in children. J. Pediatr 1996, 129:604-607.
159. Adu D., Pall A., Luqmani R.A., et al. Controlled trial of pulse versus continuous prednisolone and cyclophosphamide in the treatment of systemic vasculitis. QJM 1997, 90:401-409.
160. Guillevin L., Cordier J.F., Lhote F., et al. A prospective, multicenter, randomized trial comparing steroids and pulse cyclophosphamide versus steroids and oral cyclophosphamide in the treatment of generalized Wegener's granulomatosis. Arthritis Rheum 1997, 40:2187-2198.
161. Haubitz M., Schellong S., Gobel U., et al. Intravenous pulse administration of cyclophosphamide versus daily oral treatment in patients with antineutrophil cytoplasmic antibody- associated vasculitis and renal involvement: a prospective, randomized study. Arthritis Rheum 1998, 41:1835-1844.
162. de G.K., Adu D., Savage C.O. The value of pulse cyclophosphamide in ANCA-associated vasculitis: meta-analysis and critical review. Nephrol. Dial. Transplant 2001, 16:2018-2027.
163. de Groot G.K., Harper L., Jayne D.R., et al. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann. Intern. Med 2009, 150:670-680.
164. Harrison H.L., Linshaw M.A., Lindsley C.B., et al. Bolus corticosteroids and cyclophosphamide for initial treatment of Wegener's granulomatosis. JAMA 1980, 244:1599-1600.
165. Reinhold-Keller E., Fink C.O., Herlyn K., et al. High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate. Arthritis Rheum 2002, 47:326-332.
166. WGET Research Group Etanercept plus standard therapy for Wegener's granulomatosis. N. Engl. J. Med 2005, 352:351-361.
167. de Groot K., Rasmussen N., Bacon P.A., et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 2005, 52:2461-2469.
168. Jayne D.R., Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo. Clin. Proc 1997, 72:737-747.
169. WGET Research Group Design of the Wegener's Granulomatosis Etanercept Trial (WGET). Control Clin. Trials 2002, 23:450-468.
170. Jayne D., Rasmussen N., Andrassy K., et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med 2003, 349:36-44.
171. de Groot K., Muhler M., Reinhold-Keller E., et al. Induction of remission in Wegener's granulomatosis with low dose methotrexate. J. Rheumatol 1998, 25:492-495.
172. Langford C.A., Talar-Williams C., Sneller M.C. Use of methotrexate and glucocorticoids in the treatment of Wegener's granulomatosis: long-term renal outcome in patients with glomerulonephritis. Arthritis Rheum 2000, 43:1836-1840.
173. Sneller M.C., Hoffman G.S., Talar-Williams C., et al. An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 1995, 38:608-613.
174. Langford C.A., Talar-Williams C., Barron K.S., et al. Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am. J. Med 2003, 114:463-469.
175. Pagnoux C., Mahr A., Hamidou M.A., et al. Azathioprine or methotrexate maintenance for ANCA-associated vasculitis. N. Engl. J. Med 2008, 359:2790-2803.
176. Metzler C., Fink C., Lamprecht P., et al. Maintenance of remission with leflunomide in Wegener's granulomatosis. Rheumatology (Oxford) 2004, 43:315-320.
177. Metzler C., Miehle N., Manger K., et al. Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. Rheumatology (Oxford) 2007, 46:1087-1091.
178. Langford C.A., Talar-Williams C., Sneller M.C. Mycophenolate mofetil for remission maintenance in the treatment of Wegener's granulomatosis. Arthritis Rheum 2004, 51:278-283.
179. Nowack R., Gobel U., Klooker P., et al. Mycophenolate mofetil for maintenance therapy of Wegener's granulomatosis and microscopic polyangiitis: a pilot study in 11 patients with renal involvement. J. Am. Soc. Nephrol 1999, 10:1965-1971.
180. Stegeman C.A., Tervaert J.W., de Jong P.E., et al. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N. Engl. J. Med 1996, 335:16-20.
181. Reinhold-Keller E., de Groot K., Rudert H., et al. Response to trimethoprim/sulfamethoxazole in Wegener's granulomatosis depends on the phase of disease. QJM 1996, 89:15-23.
182. Ognibene F.P., Shelhamer J.H., Hoffman G.S., et al. Pneumocystis carinii pneumonia: a major complication of immunosuppressive therapy in patients with Wegener's granulomatosis. Am. J. Respir. Crit. Care Med 1995, 151:795-799.
183. Sowden E., Carmichael A.J. Autoimmune inflammatory disorders, systemic corticosteroids and pneumocystis pneumonia: a strategy for prevention. BMC. Infect. Dis 2004, 4:42.
184. Lamprecht P., Voswinkel J., Lilienthal T., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002, 41:1303-1307.
185. Booth A., Harper L., Hammad T., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol 2004, 15:717-721.
186. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. Rheumatology (Oxford) 2002, 41:1126-1132.
187. Josselin L., Mahr A., Cohen P., et al. Infliximab efficacy and safety against refractory systemic necrotising vasculitides: long-term follow-up of 15 patients. Ann. Rheum. Dis 2008, 67:1343-1346.
188. Wilkinson N.M., Erendzhinova E., Zeft A., et al. Infliximab as rescue therapy in three cases of paediatric Wegener's granulomatosis. Rheumatology (Oxford) 2006, 45:1047-1048.
189. Keogh K.A., Ytterberg S.R., Fervenza F.C., et al. Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial. Am. J. Respir. Crit. Care. Med 2006, 173:180-187.
190. Keogh K.A., Wylam M.E., Stone J.H., et al. Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil
191. Stasi R., Stipa E., Del P.G., et al. Long-term observation of patients with anti-neutrophil cytoplasmic antibody-associated vasculitis treated with rituximab. Rheumatology (Oxford) 2006, 45:1432-1436.
192. Eriksson P. Nine patients with anti-neutrophil cytoplasmic antibody-positive vasculitis successfully treated with rituximab. J. Intern. Med 2005, 257:540-548.
193. Smith K.G., Jones R.B., Burns S.M., et al. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and re-treatment. Arthritis Rheum 2006, 54:2970-2982.
194. Henes J.C., Fritz J., Koch S., et al. Rituximab for treatment-resistant extensive Wegener's granulomatosis: additive effects of a maintenance treatment with leflunomide. Clin. Rheumatol 2007, 26:1711-1715.
195. Brihaye B., Aouba A., Pagnoux C., et al. Adjunction of rituximab to steroids and immunosuppressants for refractory/relapsing Wegener's granulomatosis: a study on 8 patients. Clin. Exp. Rheumatol 2007, 25:S23-S27.
196. Seo P., Specks U., Keogh K.A. Efficacy of rituximab in limited Wegener's granulomatosis with refractory granulomatous manifestations. J. Rheumatol 2008, 35:2017-2023.
197. J.R. Hollister, J.B. Soep, L. Dragone, Rituximab treatment for severe Wegener's granulomatosis: a cyclophosphamide-is sparing strategy, Presented at Pediatric Rheumatology Symposium Keystone 2008.
198. Schmitt W.H., Birck R., Heinzel P.A., et al. Prolonged treatment of refractory Wegener's granulomatosis with 15-deoxyspergualin: an open study in seven patients. Nephrol. Dial. Transplant 2005, 20:1083-1092.
199. Flossmann O., Baslund B., Bruchfeld A., et al. Deoxyspergualin in relapsing and refractory Wegener's granulomatosis. Ann. Rheum. Dis 2009, 68:1125-1130.
200. Birck R., Warnatz K., Lorenz H.M., et al. 15-Deoxyspergualin in patients with refractory ANCA-associated systemic vasculitis: a six-month open-label trial to evaluate safety and efficacy. J. Am. Soc. Nephrol 2003, 14:440-447.
201. Jayne D.R., Chapel H., Adu D., et al. Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity. QJM 2000, 93:433-439.
202. Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am. J. Kidney Dis 2003, 42:1149-1153.
203. Hoffman G.S., Thomas-Golbanov C.K., Chan J., et al. Treatment of subglottic stenosis, due to Wegener's granulomatosis, with intralesional corticosteroids and dilation. J. Rheumatol 2003, 30:1017-1021.
204. Watters K., Russell J. Subglottic stenosis in Wegener's granulomatosis and the nitinol stent. Laryngoscope 2003, 113:2222-2224.
205. Roediger F.C., Orloff L.A., Courey M.S. Adult subglottic stenosis: management with laser incisions and mitomycin-C. Laryngoscope 2008, 118:1542-1546.
206. Smith M.E., Elstad M. Mitomycin C and the endoscopic treatment of laryngotracheal stenosis: are two applications better than one?. Laryngoscope 2009, 119:272-283.
207. Walton E.W. Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis). Br. Med. J 1958, 2:265-270.
208. Booth A.D., Almond M.K., Burns A., et al. Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am. J. Kidney Dis 2003, 41:776-784.
209. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients. Arthritis Rheum 2000, 43:1021-1032.
210. Matteson E.L., Gold K.N., Bloch D.A., et al. Long-term survival of patients with Wegener's granulomatosis from the American College of Rheumatology Wegener's Granulomatosis Classification Criteria Cohort. Am. J. Med 1996, 101:129-134.
211. Luqmani R.A., Bacon P.A., Moots R.J., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM 1994, 87:671-678.
212. Exley A.R., Bacon P.A., Luqmani R.A., et al. Examination of disease severity in systemic vasculitis from the novel perspective of damage using the vasculitis damage index (VDI). Br. J. Rheumatol 1998, 37:57-63.
213. Guillevin L., Visser H., Noel L.H., et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatitis B virus infection and Churg-Strauss syndrome-62 patients. J. Rheumatol 1993, 20:1345-1349.
214. Churg J., Strauss L. Allergic granulomatosis, allergic angiitis, and periarteritis nodosa. Am. J. Pathol 1951, 27:277-301.
215. Lanham J.G., Elkon K.B., Pusey C.D., et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984, 63:65-81.
216. R.A. Watts, D.G. Scott, Lanese epidemiology of Wegener's granulomatosis, microscopic polyangiitis and Churg-Strauss syndrome. Cleve. Clin. J. Med. 69 (Suppl. 2) (2003) S1184-S1186.
217. Gonzalez-Gay M.A., Garcia-Porrua C., Guerrero J., et al. The epidemiology of the primary systemic vasculitides in northwest Spain: implications of the Chapel Hill Consensus Conference definitions. Arthritis Rheum 2003, 49:388-393.
218. Zwerina J., Eger G., Englbrecht M., et al. Churg-Strauss syndrome in childhood: a systematic literature review and clinical comparison with adult patients. Semin. Arthritis Rheum 2008, 39:108-115.
219. Guillevin L., Cohen P., Gayraud M., et al. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore) 1999, 78:26-37. 1999.
220. Sinico R.A., Di Toma L., Maggiore U., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935.
221. Sable-Fourtassou R., Cohen P., Mahr A., et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann. Intern. Med 2005, 143:632-638.
222. Sinico R.A., Di Toma L., Maggiore U., et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005, 52:2926-2935.
223. Tai P.C., Holt M.E., Denny P., et al. Deposition of eosinophil cationic protein in granulomas in allergic granulomatosis and vasculitis: the Churg-Strauss syndrome. Br. Med. J. Clin. Res. Ed 1984, 289:400-402.
224. Tai P.C., Ackerman S.J., Spry C.J., et al. Deposits of eosinophil granule proteins in cardiac tissues of patients with eosinophilic endomyocardial disease. Lancet 1987, 1:643-647.
225. Keogh K.A., Specks U. Churg-Strauss syndrome: clinical presentation, antineutrophil cytoplasmic antibodies, and leukotriene receptor antagonists. Am. J. Med 2003, 115:284-290.
226. Kallenberg C.G. Churg-Strauss syndrome: just one disease entity?. Arthritis Rheum 2005, 52:2589-2593.
227. Weller P.F., Plaut M., Taggart V., et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J. Allergy Clin. Immunol 2001, 108:175-183.
228. Chumbley L.C., Harrison E.G., DeRemee R.A. Allergic granulomatosis and angiitis (Churg-Strauss syndrome): report and analysis of 30 cases. Mayo. Clin. Proc 1977, 52:477-484.
229. Guillevin L., Guittard T., Bletry O., et al. Systemic necrotizing angiitis with asthma: causes and precipitating factors in 43 cases. Lung 1987, 165:165-172.
230. Davis M.D., Daoud M.S., McEvoy M.T., et al. Cutaneous manifestations of Churg-Strauss syndrome: a clinicopathologic correlation. J. Am. Acad. Dermatol 1997, 37:199-203.
231. Gaskin G., Clutterbuck E.J., Pusey C.D. Renal disease in the Churg-Strauss syndrome: diagnosis, management and outcome. Contrib. Nephrol 1991, 94:58-65.
232. Cury D., Breakey A.S., Payne B.F. Allergic granulomatous angiitis associated with uveoscleritis and papilledema. Arch. Ophthalmol 1956, 55:261-266.
233. Sehgal M., Swanson J.W., DeRemee R.A., et al. Neurologic manifestations of Churg-Strauss syndrome. Mayo. Clin. Proc 1995, 70:337-341.
234. Hattori N., Mori K., Misu K., et al. Mortality and morbidity in peripheral neuropathy associated Churg-Strauss syndrome and microscopic polyangiitis. J. Rheumatol 2002, 29:1408-1414.
235. Pagnoux C., Mahr A., Cohen P., et al. Presentation and outcome of gastrointestinal involvement in systemic necrotizing vasculitides: analysis of 62 patients with polyarteritis nodosa, microscopic polyangiitis, Wegener granulomatosis, Churg-Strauss syndrome, or rheumatoid arthritis-associated vasculitis. Medicine (Baltimore) 2005, 84:115-128.
236. Finan M.C., Winkelmann R.K. The cutaneous extravascular necrotizing granuloma (Churg-Strauss granuloma) and systemic disease: a review of 27 cases. Medicine (Baltimore) 1983, 62:142-158.
237. Wallaert B., Gosset P., Prin L., et al. Bronchoalveolar lavage in allergic granulomatosis and angiitis. Eur. Respir. J 1993, 6:413-417.
238. Schnabel A., Csernok E., Braun J., et al. Inflammatory cells and cellular activation in the lower respiratory tract in Churg-Strauss syndrome. Thorax 1999, 54:771-778.
239. Treitman P., Herskowitz J.L., Bass H.N. Churg-Strauss syndrome in a 14-year-old boy diagnosed by transbronchial lung biopsy. Clin. Pediatr. (Phila.) 1991, 30:502-505.
240. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome: a prospective study in 342 patients. Medicine (Baltimore) 1996, 75:17-28.
241. Assaf C., Mewis G., Orfanos C.E., et al. Churg-Strauss syndrome: successful treatment with mycophenolate mofetil. Br. J. Dermatol 2004, 150:598-600.
242. Della R.A., Baldini C., Tavoni A., et al. Churg-Strauss syndrome: clinical and serological features of 19 patients from a single Italian centre. Rheumatology (Oxford) 2002, 41:1286-1294.
243. Metzler C., Hellmich B., Gause A., et al. Churg Strauss syndrome: successful induction of remission with methotrexate and unexpected high cardiac and pulmonary relapse ratio during maintenance treatment. Clin. Exp. Rheumatol 2004, 22:S52-S61.
244. Tatsis E., Schnabel A., Gross W.L. Interferon-alpha treatment of four patients with the Churg-Strauss syndrome. Ann. Intern. Med 1998, 129:370-374.
245. Koukoulaki M., Smith K.G., Jayne D.R. Rituximab in Churg-Strauss syndrome. Ann. Rheum. Dis 2006, 65:557-559.
246. Lane S.E., Watts R.A., Shepstone L., et al. Primary systemic vasculitis: clinical features and mortality. QJM 2005, 98:97-111.
247. Davson J., Ball J., Platt R. The kidney in periarteritis nodosa. Q. J. Med 1948, 17:175-202.
248. Savage C.O., Winearls C.G., Evans D.J., et al. Microscopic polyarteritis: presentation, pathology and prognosis. Q. J. Med 1985, 56:467-483.
249. Watts R.A., Jolliffe V.A., Carruthers D.M., et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996, 39:1208-1212.
250. Watts R., Lane S., Hanslik T., et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann. Rheum. Dis 2007, 66:222-227.
251. Mohammad A.J., Jacobsson L.T., Mahr A.D., et al. Prevalence of Wegener's granulomatosis, microscopic polyangiitis, polyarteritis nodosa and Churg-Strauss syndrome within a defined population in southern Sweden. Rheumatology (Oxford) 2007, 46:1329-1337.
252. Adu D., Howie A.J., Scott D.G., et al. Polyarteritis and the kidney. Q. J. Med 1987, 62:221-237.
253. Hattori M., Kurayama H., Koitabashi Y. Antineutrophil cytoplasmic autoantibody-associated glomerulonephritis in children. J. Am. Soc. Nephrol 2001, 12:1493-1500.
254. Yu F., Zhao M.H., Huang J.P., et al. Clinical and pathological features of anti-neutrophil cytoplasm antibody associated systemic vasculitis in children. Zhonghua. Er. Ke. Za. Zhi 2003, 41:831-834.
255. Besbas N., Ozen S., Saatci U., et al. Renal involvement in polyarteritis nodosa: evaluation of 26 Turkish children. Pediatr. Nephrol 2000, 14:325-327.
256. Peco-Antic A., Bonaci-Nikolic B., Basta-Jovanovic G., et al. Childhood microscopic polyangiitis associated with MPO-ANCA. Pediatr. Nephrol 2006, 21:46-53.
257. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: clinical and laboratory findings in eighty-five patients. Arthritis Rheum 1999, 42:421-430.
258. Charles L.A., Caldas M.L., Falk R.J., et al. Antibodies against granule proteins activate neutrophils in vitro. J. Leukoc. Biol 1991, 50:539-546.
259. Falk R.J., Terrell R.S., Charles L.A., et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. U. S. A 1990, 87:4115-4119.
260. Xiao H., Heeringa P., Liu Z., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am. J. Pathol 2005, 167:39-45.
261. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J. Clin. Invest 2002, 110:955-963.
262. Schlieben D.J., Korbet S.M., Kimura R.E., et al. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am. J. Kidney. Dis 2005, 45:758-761.
263. Bansal P.J., Tobin M.C. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann. Allergy Asthma Immunol 2004, 93:398-401.
264. Serra A., Cameron J.S., Turner D.R., et al. Vasculitis affecting the kidney: presentation, histopathology and long-term outcome. Q. J. Med 1984, 53:181-207.
265. Oh J.S., Lee C.K., Kim Y.G., et al. Clinical features and outcomes of microscopic polyangiitis in Korea. J. Korean. Med. Sci 2009, 24:269-274.
266. Seishima M., Oyama Z., Oda M. Skin eruptions associated with microscopic polyangiitis. Eur. J. Dermatol 2004, 14:255-258.
267. Nagai Y., Hasegawa M., Igarashi N., et al. Cutaneous manifestations and histological features of microscopic polyangiitis. Eur. J. Dermatol 2009, 19:57-60.
268. Kawakami T., Kawanabe T., Saito C., et al. Clinical and histopathologic features of 8 patients with microscopic polyangiitis including two with a slowly progressive clinical course. J. Am. Acad. Dermatol 2007, 57:840-848.
269. Niiyama S., Amoh Y., Tomita M., et al. Dermatological manifestations associated with microscopic polyangiitis. Rheumatol. Int 2008, 28:593-595.
270. Jayne D.R., Marshall P.D., Jones S.J., et al. Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. Kidney Int 1990, 37:965-970.
271. Bakkaloglu A., Ozen S., Baskin E., et al. The significance of antineutrophil cytoplasmic antibody in microscopic polyangitis and classic polyarteritis nodosa. Arch. Dis. Child 2001, 85:427-430.
272. Guillevin L., Lhote F. Polyarteritis nodosa and microscopic polyangiitis. Clin. Exp. Immunol 1995, 101:22-23.
273. Jennette J.C., Falk R.J. The coming of age of serologic testing for anti-neutrophil cytoplasmic autoantibodies. Mayo. Clin. Proc 1994, 69:908-910.
274. Cohen P., Guillevin L., Baril L., et al. Persistence of antineutrophil cytoplasmic antibodies (ANCA) in asymptomatic patients with systemic polyarteritis nodosa or Churg-Strauss syndrome: follow-up of 53 patients. Clin. Exp. Rheumatol 1995, 13:193-198.
275. Falk R.J., Jennette J.C. ANCA small-vessel vasculitis. J. Am. Soc. Nephrol 1997, 8:314-322.
276. Gayraud M., Guillevin L., le Toulemin P., et al. Long-term followup of polyarteritis nodosa, microscopic polyangiitis, and Churg-Strauss syndrome: analysis of four prospective trials including 278 patients. Arthritis Rheum 2001, 44:666-675.
277. Kaiser M., Younge B., Bjornsson J., et al. Formation of new vasa vasorum in vasculitis: production of angiogenic cytokines by multinucleated giant cells. Am. J. Pathol 1999, 155:765-774.
278. O'Neil K.M. Progress in pediatric vasculitis. Curr. Opin. Rheumatol 2009, 21:538-546.
279. Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Takayasu arteritis and giant cell arteritis: a spectrum within the same disease?. Medicine (Baltimore) 2009, 88:221-226.
280. Emmerich J., Fiessinger J.N. Epidemiology and etiological factors in giant cell arteritis (Horton's disease and Takayasu's disease). Ann. Med. Interne. (Paris) 1998, 149:425-432.
281. Lie J.T. Bilateral juvenile temporal arteritis. J. Rheumatol 1995, 22:774-776.
282. Bert R.J., Antonacci V.P., Berman L., et al. Polyarteritis nodosa presenting as temporal arteritis in a 9-year-old child. Am. J. Neuroradiol 1999, 20:167-171.
283. Numano F. The story of Takayasu arteritis. Rheumatology (Oxford) 2002, 41:103-106.
284. Cakar N., Yalcinkaya F., Duzova A., et al. Takayasu arteritis in children. J. Rheumatol 2008, 35:913-919.
285. Bloch D.A., Michel B.A., Hunder G.G., et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthritis Rheum 1990, 33:1068-1073.
286. O.R. Tann, R.M.R. Tulloh, M.C.K. Hamilton, Takayasu's disease: a review, Cardiol. Young. 18 (2008) 250-259.
287. Lane S.E., Watts R., Scott D.G. Epidemiology of systemic vasculitis. Curr. Rheumatol. Rep 2005, 7:270-275.
288. Watts R.A., Scott D.G. Epidemiology of the vasculitides. Curr. Opin. Rheumatol 2003, 15:11-16.
289. Fraga A., Medina F. Takayasu's arteritis. Curr. Rheumatol. Rep 2002, 4:30-38.
290. Jain S., Kumari S., Ganguly N.K., et al. Current status of Takayasu arteritis in India. Int. J. Cardiol 1996, 54:S111-S116.
291. Dabague J., Reyes P.A. Takayasu arteritis in Mexico: a 38-year clinical perspective through literature review. Int. J. Cardiol 1996, 54:S103-S109.
292. Hahn D., Thomson P.D., Kala U., et al. A review of Takayasu's arteritis in children in Gauteng, South Africa. Pediatr. Nephrol 1998, 12:668-675.
293. Muranjan M.N., Bavdekar S.B., More V., et al. Study of Takayasu's arteritis in children: clinical profile and management. J. Postgrad. Med 2000, 46:3-8.
294. Watts R., Al-Taiar A., Mooney J., et al. The epidemiology of Takayasu arteritis in the UK. Rheumatology (Oxford) 2009, 48:1008-1011.
295. Ruige J.B., Van G.C., Nevelsteen A., et al. A 16-year survey of Takayasu's arteritis in a tertiary Belgian center. Int. Angiol 2003, 22:414-420.
296. Pantell R.H., Goodman B.W. Takayasu's arteritis: the relationship with tuberculosis. Pediatr 1981, 67:84-88.
297. Aggarwal A., Chag M., Sinha N., et al. Takayasu's arteritis: role of Mycobacterium tuberculosis and its 65 kDa heat shock protein. Int. J. Cardiol 1996, 55:49-55.
298. Rose A.G., Sinclair-Smith C.C. Takayasu's arteritis: a study of 16 autopsy cases. Arch. Pathol. Lab. Med 1980, 104:231-237.
299. Jain S., Sharma N., Singh S., et al. Takayasu arteritis in children and young Indians. Int. J. Cardiol 2000, 75:S153-S157.
300. Kinare S.G. Cardiac lesions in non-specific aorto-arteritis: an autopsy study. Indian Heart J 1994, 46:65-69.
301. Kinare S.G. Nonspecific aortitis (Takayasu's disease): autopsy study of 35 cases. Pathol. Microbiol. (Basel) 1975, 43:134-139.
302. Numano F., Isohisa I., Maezawa H., et al. HL-A antigens in Takayasu's disease. Am. Heart J 1979, 98:153-159.
303. Soto M.E., Vargas-Alarcon G., Cicero-Sabido R., et al. Comparison distribution of HLA-B alleles in Mexican patients with Takayasu arteritis and tuberculosis. Hum. Immunol 2007, 68:449-453.
304. Kerr G. Takayasu's arteritis. Curr. Opin. Rheumatol 1994, 6:32-38.
305. Park M.C., Lee S.W., Park Y.B., et al. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006, 45:545-548.
306. Morales E., Pineda C., Martinez-Lavin M. Takayasu's arteritis in children. J. Rheumatol 1991, 18:1081-1084.
307. Ozen S., Bakkaloglu A., Dusunsel R., et al. Childhood vasculitides in Turkey: a nationwide survey. Clin. Rheumatol 2007, 26:196-200.
308. Piyachon C., Suwanwela N. Takayasu arteritis in Thailand. Heart Vessels (Suppl.) 1992, 7:60-67.
309. Sharma B.K., Sagar S., Singh A.P., et al. Takayasu arteritis in India. Heart Vessels (Suppl.) 1992, 7:37-43.
310. Zheng D., Fan D., Liu L. Takayasu arteritis in China: a report of 530 cases. Heart Vessels (Suppl.) 1992, 7:32-36.
311. Turkoglu C., Memis A., Payzin S., et al. Takayasu arteritis in Turkey. Int. J. Cardiol 1996, 54:S135-S136.
312. Hilario M.O., Terreri M.T., Prismich G., et al. Association of ankylosing spondylitis, Crohn's disease and Takayasu's arteritis in a child. Clin. Exp. Rheumatol 1998, 16:92-94.
313. Iizuka B., Yamagishi N., Honma N., et al. Cardiovascular disease associated with ulcerative colitis. Nippon. Rinsho 1999, 57:2540-2545.
314. Reny J.L., Paul J.F., Lefebvre C., et al. Association of Takayasu's arteritis and Crohn's disease: results of a study on 44 Takayasu patients and review of the literature. Ann. Med. Interne. (Paris) 2003, 154:85-90.
315. Dagan O., Barak Y., Metzker A. Pyoderma gangrenosum and sterile multifocal osteomyelitis preceding the appearance of Takayasu arteritis. Pediatr. Dermatol 1995, 12:39-42.
316. Hall S., Nelson A.M. Takayasu's arteritis and juvenile rheumatoid arthritis. J. Rheumatol 1986, 13:431-433.
317. Wu H., Virdi A. Refractory abdominal pain: atypical presentation of Takayasu's arteritis. Pain Med 2009, 10:941-943.
318. Karande S., Jagtap S., Joshi A. Posterior reversible encephalopathy syndrome revealing Takayasu's arteritis. Indian J. Pediatr 2009, 76:218-220.
319. Kaliaperumal S., Gupta A., Sengupta S., et al. Unilateral hemorrhagic keratouveitis as the initial presentation of Takayasu's arteritis. Indian. J. Ophthalmol 2007, 55:397-398.
320. Worrall M., Atebara N., Meredith T., et al. Bilateral ocular ischemic syndrome in Takayasu disease. Retina 2001, 21:75-76.
321. Ghosn S., Malek J., Shbaklo Z., et al. Takayasu disease presenting as malignant pyoderma gangrenosum in a child with relapsing polychondritis. J. Am. Acad. Dermatol 2008, 59:S84-S87.
322. Janzen J., Vuong P.N., Rothenberger-Janzen K. Takayasu's arteritis and fibromuscular dysplasia as causes of acquired atypical coarctation of the aorta: retrospective analysis of seven cases. Heart Vessels 1999, 14:277-282.
323. Bayrak A.H., Numan F., Cantasdemir M., et al. Percutaneous balloon angioplasty of renovascular hypertension in pediatric cases. Acta. Chir. Belg 2008, 108:708-714.
324. Sueyoshi E., Sakamoto I., Uetani M. MRI of Takayasu's arteritis: typical appearances and complications. Am. J. Roentgenol 2006, 187:W569-W575.
325. Homme J.L., Aubry M.C., Edwards W.D., et al. Surgical pathology of the ascending aorta: a clinicopathologic study of 513 cases. Am. J. Surg. Pathol 2006, 30:1159-1168.
326. Kaiser M., Weyand C.M., Bjornsson J., et al. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum 1998, 41:623-633.
327. Sharma B.K., Jain S., Radotra B.D. An autopsy study of Takayasu arteritis in India. Int. J. Cardiol 1998, 66:S85-S90.
328. Hotchi M. Pathological studies on Takayasu arteritis. Heart Vessels (Suppl.) 1992, 7:11-17.
329. Appenzeller S., Faria A.V., Zanardi V.A., et al. Vascular involvement of the central nervous system and systemic diseases: etiologies and MRI findings. Rheumatol. Int 2008, 28:1229-1237.
330. Aluquin V.P., Albano S.A., Chan F., et al. Magnetic resonance imaging in the diagnosis and follow up of Takayasu's arteritis in children. Ann. Rheum. Dis 2002, 61:526-529.
331. Maksimowicz-McKinnon K., Clark T.M., Hoffman G.S. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007, 56:1000-1009.
332. Tso E., Flamm S.D., White R.D., et al. Takayasu arteritis: utility and limitations of magnetic resonance imaging in diagnosis and treatment. Arthritis Rheum 2002, 46:1634-1642.
333. Hoffmann M., Corr P., Robbs J. Cerebrovascular findings in Takayasu disease. J. Neuroimaging 2000, 10:84-90.
334. Arnaud L., Haroche J., Malek Z., et al. Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis?. Arthritis Rheum 2009, 60:1193-1200.
335. Bartels A.L., Zeebregts C.J., Bijl M., et al. Fused FDG-PET and MRI imaging of Takayasu arteritis in vertebral arteries. Ann. Nucl. Med 2009, 23:753-756.
336. McCulloch M., Andronikou S., Goddard E., et al. Angiographic features of 26 children with Takayasu's arteritis. Pediatr. Radiol 2003, 33:230-235.
337. Baumgartner D., Sailer-Hock M., Baumgartner C., et al. Reduced aortic elastic properties in a child with Takayasu arteritis: case report and literature review. Eur. J. Pediatr 2005, 164:685-690.
338. Seth S., Goyal N.K., Jagia P., et al. Carotid intima-medial thickness as a marker of disease activity in Takayasu's arteritis. Int. J. Cardiol 2006, 108:385-390.
339. Ozen S., Duzova A., Bakkaloglu A., et al. Takayasu arteritis in children: preliminary experience with cyclophosphamide induction and corticosteroids followed by methotrexate. J. Pediatr 2007, 150:72-76.
340. Filocamo G., Buoncompagni A., Viola S., et al. Treatment of Takayasu's arteritis with tumor necrosis factor antagonists. J. Pediatr 2008, 153:432-434.
341. Hoffman G.S., Merkel P.A., Brasington R.D., et al. Anti-tumor necrosis factor therapy in patients with difficult to treat Takayasu arteritis. Arthritis Rheum 2004, 50:2296-2304.
342. Lee B.B., Laredo J., Neville R., et al. Endovascular management of Takayasu arteritis: is it a durable option?. Vascular 2009, 17:138-146.
343. Kalangos A., Christenson J.T., Cikirikcioglu M., et al. Long-term outcome after surgical intervention and interventional procedures for the management of Takayasu's arteritis in children. J. Thorac. Cardiovasc. Surg 2006, 132:656-664.
344. Phillip R., Luqmani R. Mortality in systemic vasculitis: a systematic review. Clin. Exp. Rheumatol 2008, 26:S94-S104.
345. M.E. Soto, N. Espinola, L.F. Flores-Suarez P.A. Reyes, Takayasu arteritis: Clinical features in 110 Mexican Mestizo patients and cardiovascular impact on survival and prognosis, Clin. Exp. Rheumatol. 26 (3 Suppl. 49) (2008) S9-S15.
346. Harbitz P. Unknown forms of arteritis with special reference to their relation to syphilitic arteritis and periarteritis nodosa. Am. J. Med. Sci 1922, 163:250-272.
347. Cravioto H., Feigin I. Noninfectious granulomatous angiitis with predilection for the nervous system. Neurology 1959, 9:599-609.
348. Calabrese L.H., Mallek J.A. Primary angiitis of the central nervous system: report of 8 new cases, review of the literature, and proposal for diagnostic criteria. Medicine 1988, 67:20-39.
349. Calabrese L.H. Vasculitis of the central nervous system. Rheum. Dis. Clin. North Am 1995, 21:1059-1076.
350. Calabrese L.H., Furlan A.J., Gragg L.A., et al. Primary angiitis of the central nervous system: diagnostic criteria and clinical approach. Cleve. Clin. J. Med 1992, 59:293-306.
351. Lanthier S., Lortie A., Michaud J., et al. Isolated angiitis of the CNS in children. Neurology 2001, 56:837-842.
352. Gallagher K.T., Shaham B., Reiff A., et al. Primary angiitis of the central nervous system in children: 5 cases. J. Rheumatol 2001, 28:616-623.
353. Benseler S.M., Silverman E., Aviv R.I., et al. Primary central nervous system vasculitis in children. Arthritis Rheum 2006, 54:1291-1297.
354. Benseler S.M., deVeber G., Hawkins C., et al. Angiography-negative primary central nervous system vasculitis in children: a newly recognized inflammatory central nervous system disease. Arthritis Rheum 2005, 52:2159-2167.
355. Banwell B., Tenembaum S., Lennon V.A., et al. Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders. Neurology 2008, 70:344-352.
356. Florance N.R., Davis R.L., Lam C., et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann. Neurol 2009, 66:11-18.
357. Moshous D., Feyen O., Lankisch P., et al. Primary necrotizing lymphocytic central nervous system vasculitis due to perforin deficiency in a four-year-old girl. Arthritis Rheum 2007, 56:995-999.
358. K.G. Werner, C.F. Morel, A. Kirton, et al., RoME: rolandic mitochondrial encephalomyelopathy with epilepsia partialis continua and ND3 mutations, Ped. Neurol. 41 (2009) 27-33.
359. Carroll M.B. MELAS masquerading as a systemic vasculitis. J. Clin. Rheumatol 2007, 13:334-337.
360. Elbers J., Benseler S.M. Central nervous system vasculitis in children. Curr. Opin. Rheumatol 2008, 20:47-54.
361. Ganesan V., Chong W.K., Cox T.C., et al. Posterior circulation stroke in childhood: risk factors and recurrence. Neurology 2002, 59:1552-1556.
362. Askalan R., Laughlin S., Mayank S., et al. Chickenpox and stroke in childhood: a study of frequency and causation. Stroke 2001, 32:1257-1262.
363. Fullerton H., Lynch J.K., deVeber G. The call for multicenter studies of pediatric stroke. Stroke 2006, 37:330-331.
364. deVeber G., Roach E.S., Riela A.R., et al. Stroke in children: recognition, treatment, and future directions. Semin. Pediatr. Neurol 2000, 7:309-317.
365. Giroud M., Lemesle M., Gouyon J.B., et al. Cerebrovascular disease in children under 16 years of age in the city of Dijon, France: a study of incidence and clinical features from 1985 to 1993. J. Clin. Epidemiol 1995, 48:1343-1348.
366. Lynch J.K., Hirtz D.G., DeVeber G., et al. Report of the National Institute of Neurological Disorders and Stroke workshop on perinatal and childhood stroke. Pediatrics 2002, 109:116-123.
367. Golomb M.R., Fullerton H.J., Nowak-Gottl U., et al. Male predominance in childhood ischemic stroke: findings from the international pediatric stroke study. Stroke 2009, 40:52-57.
368. Banwell B., Kennedy J., Sadovnick D., et al. Incidence of acquired demyelination of the CNS in Canadian children. Neurology 2009, 72:232-239.
369. Yaari R., Anselm I.A., Szer I.S., et al. Childhood primary angiitis of the central nervous system: two biopsy-proven cases. J. Pediatr 2004, 145:693-697.
370. Venkateswaran S., Hawkins C., Wassmer E. Diagnostic yield of brain biopsies in children presenting to neurology. J. Child Neurol 2008, 23:253-258.
371. A. Fawcett, L. Verhey, H. Branson, et al., Comparison of magnetic resonance imaging features of inflammatory disorders of the CNS in Children (2009) (unpublished).
372. Swartz R.H., Bhuta S.S., Farb R.I., et al. Intracranial arterial wall imaging using high-resolution 3-tesla contrast-enhanced MRI. Neurology 2009, 72:627-634.
373. Kuker W., Gaertner S., Nagele T., et al. Vessel wall contrast enhancement: a diagnostic sign of cerebral vasculitis. Cerebrovasc. Dis 2008, 26:23-29.
374. Gargus J.J. Ion channel functional candidate genes in multigenic neuropsychiatric disease. Biol. Psychiatry 2006, 60:177-185.
375. Hajj-Ali R.A., Calabrese L.H. Central nervous system vasculitis. Curr. Opin. Rheumatol 2009, 21:10-18.
376. Kirton A., Diggle J., Hu W., et al. A pediatric case of reversible segmental cerebral vasoconstriction. Can. J. Neurol. Sci 2006, 33:250-253.
377. Elbers J., Halliday W., Hawkins C., et al. Brain biopsy characteristics in children with small vessel central nervous system vasculitis. Ann. Neurol. 2009, (in press).
378. Engelsen B.A., Tzoulis C., Karlsen B., et al. POLG1 mutations cause a syndromic epilepsy with occipital lobe predilection. Brain 2008, 131:818-828.
379. Wolf N.I., Rahman S., Schmitt B., et al. Status epilepticus in children with Alpers' disease caused by POLG1 mutations: EEG and MRI features. Epilepsia 2009, 50:1596-1607.
380. Werner K.G., Morel C.F., Kirton A., et al. Rolandic mitochondrial encephalomyelopathy and MT-ND3 mutations. Pediatr. Neurol 2009, 41:27-33.
381. Shimazaki H., Morita M., Nakano I., et al. Inverse ocular bobbing in a patient with encephalitis associated with antibodies to the N-methyl-D-aspartate receptor. Arch. Neurol 2008, 65:1251.
382. Parratt K.L., Allan M., Lewis S.J., et al. Acute psychiatric illness in a young woman: an unusual form of encephalitis. Med. J. Aust 2009, 191:284-286.
383. McKeon A., Lennon V.A., Lotze T., et al. CNS aquaporin-4 autoimmunity in children. Neurology 2008, 71:93-100.
384. Debette S., de Seze J., Pruvo J.P., et al. Long-term outcome of acute and subacute myelopathies. J. Neurol 2009, 256:980-988.
385. Myung J., Kim B., Yoon B.W., et al. B-cell dominant lymphocytic primary angiitis of the central nervous system: four biopsy-proven cases. Neuropathology 2009.
386. Aviv R.I., Benseler S.M., Silverman E.D., et al. MR imaging and angiography of primary CNS vasculitis of childhood. AJNR 2006, 27:192-199.
387. Hutchinson C., Elbers J., Halliday W., et al. Open label study for treatment of angiography-negative, biopsy-positive primary CNS vasculitis in children. Presented at Pediatric Rheumatology Symposium Keystore 2008, Arthritis Rheum 2008, 58.
388. Aviv R.I., Benseler S.M., DeVeber G., et al. Angiography of primary central nervous system angiitis of childhood: conventional angiography versus magnetic resonance angiography at presentation. AJNR 2007, 28:9-15.
389. Barron T.F., Ostrov B.E., Zimmerman R.A., et al. Isolated angiitis of CNS: treatment with pulse cyclophosphamide. Pediatr. Neurol 1993, 9:73-75.
390. Soon G., Yau I., Branson H., et al. Non-progressive primary CNS vasculitis in children: immunosuppression reduces recurrent ischemic event risk. Arthritis Rheum 2008, 58(Suppl):S942.
391. Kirton A., deVeber G. Therapeutic approaches and advances in pediatric stroke. NeuroRx 2006, 3:133-142.
392. Molloy E.S., Langford C.A., Clark T.M., et al. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann. Rheum. Dis 2008, 67:1567-1569.
393. Dale R.C., Brilot F., Banwell B. Pediatric central nervous system inflammatory demyelination: acute disseminated encephalomyelitis, clinically isolated syndromes, neuromyelitis optica, and multiple sclerosis. Curr. Opin. Neurol 2009, 22:233-240.
394. Fowler A., Stodberg T., Eriksson M., et al. Childhood encephalitis in
395. Fowlkes A.L., Honarmand S., Glaser C., et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J. Infect. Dis 2008, 198:1685-1691.
396. Doja A., Bitnun A., Ford Jones E.L., et al. Pediatric Epstein-Barr virus-associated encephalitis: 10-year review. J. Child Neurol 2006, 21:384-391.
397. Ilias A., Galanakis E., Raissaki M., et al. Childhood encephalitis in Crete, Greece. J. Child Neurol 2006, 21:910-912.
398. Christie L.J., Honarmand S., Talkington D.F., et al. Pediatric encephalitis: what is the role of Mycoplasma pneumoniae?. Pediatrics 2007, 120:305-313.
399. Banerjee B., Petersen K. Psychosis following mycoplasma pneumonia. Mil. Med 2009, 174:1001-1004.
400. Gerwig M., Kastrup O., Wanke I., et al. Adult post-infectious thalamic encephalitis: acute onset and benign course. Eur. J. Neurol 2004, 11:135-139.
401. Bitnun A., Ford-Jones E.L., Petric M., et al. Acute childhood encephalitis and Mycoplasma pneumoniae. Clin. Infect. Dis 2001, 32:1674-1684.
402. Daxboeck F., Blacky A., Seidl R., et al. Diagnosis, treatment, and prognosis of Mycoplasma pneumoniae childhood encephalitis: systematic review of 58 cases. J. Child Neurol 2004, 19:865-871.
403. Lennon V.A., Kryzer T.J., Pittock S.J., et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med 2005, 202:473-477.
404. Jacob A., Weinshenker B.G., Violich I., et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neuro 2008, 65:1443-1448.
405. Pranzatelli M.R., Travelstead A.L., Tate E.D., et al. CSF B-cell expansion in opsoclonus-myoclonus syndrome: a biomarker of disease activity. Mov. Disord 2004, 19:770-777.
406. Rothenberg A.B., Berdon W.E., D'Angio G.J., et al. The association between neuroblastoma and opsoclonus-myoclonus syndrome: a historical review. Pediatr. Radiol 2009, 39:723-726.
407. Kirsten A., Beck S., Fuhlhuber V., et al. New autoantibodies in pediatric opsoclonus myoclonus syndrome. Ann. N. Y. Acad. Sci 2007, 1110:256-260.
408. Ki Pang K., de Sousa C., Lang B., et al. A prospective study of the presentation and management of dancing eye syndrome/opsoclonus-myoclonus syndrome in the United Kingdom. Eur. J. Paediatr. Neurol 2009, 14:156-161.
409. Pranzatelli M.R., Tate E.D., Travelstead A.L., et al. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J. Clin. Immunol 2009, 30:106-113.
410. Burke M.J., Cohn S.L. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. Pediatr. Blood Cancer 2008, 50:679-680.
411. Ertle F., Behnisch W., Al Mulla N.A., et al. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses. Pediatr. Blood Cancer 2008, 50:683-687.
412. Stockler-Ipsiroglu S., Plecko B. Metabolic epilepsies: approaches to a diagnostic challenge. Can. J. Neurol. Sci 2009, 36:S67-S72.
413. Sternberg D., Chatzoglou E., Laforet P., et al. Mitochondrial DNA transfer RNA gene sequence variations in patients with mitochondrial disorders. Brain 2001, 124:984-994.
414. Wiltshire E., Davidzon G., DiMauro S., et al. Juvenile Alpers disease. Arch. Neuro 2008, 65:121-124.
415. Hasselmann O., Blau N., Ramaekers V.T., et al. Cerebral folate deficiency and CNS inflammatory markers in Alpers disease. Mol. Genet. Metab 2009, 99:58-61.